SCHEMBL5769083

SCHEMBL5769083

CC(C)(C)OC(=O)N1CC2CCC(C1)c1cc(C#N)ccc12

nearest known ligand 0.49

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
GPR119 Q8TDV5 9/20 0.49
IRAK4 Q9NWZ3 1/20 0.46
KDM4E B2RXH2 1/20 0.45
EGLN2 Q96KS0 2/20 0.43
AR P10275 1/20 0.41
MEN1 O00255 1/20 0.41
ALDH1A1 P00352 1/20 0.41
MAPT P10636 1/20 0.41
KMT2A Q03164 1/20 0.41
CHRNA1 P02708 1/20 0.41
CHRNG P07510 1/20 0.41
CHRNB1 P11230 1/20 0.41
CHRNB2 P17787 1/20 0.41
CHRNB4 P30926 1/20 0.41
CHRNA3 P32297 1/20 0.41
CHRNA4 P43681 1/20 0.41
CHRND Q07001 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4409738 0.93 KDM4E (0.50) GPR119IRAK4KDM4EEGLN2AR
Hydrochloric Acid SCHEMBL6824751 0.86 CHRNB2 (0.58) GPR119IRAK4KDM4EEGLN2AR
SCHEMBL25888624 0.85 GPR119 (0.47) GPR119IRAK4KDM4EEGLN2AR
SCHEMBL31421094 0.81 USP30 (0.51) GPR119KDM4E
SCHEMBL5769158 0.81 KDM4E (0.50) GPR119KDM4EMAPT
SCHEMBL15601524 0.81 GPR119 (0.54) GPR119KDM4EEGLN2AR
SCHEMBL30976364 0.80 GPR119 (0.52) GPR119IRAK4EGLN2
Hydrochloric Acid SCHEMBL28007262 0.80 GPR119 (0.53) GPR119KDM4EEGLN2AR
SCHEMBL17629880 0.78 GPR119 (0.54) GPR119IRAK4KDM4EEGLN2MAPT
SCHEMBL20346929 0.78 GPR119 (0.58) GPR119IRAK4KDM4EMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1648872-A2 ARYL FUSED AZAPOLYCYCLIC COMPOUNDS Pfizer Products Inc. (US) 2006-04-26 EP claimed
WO-2005007630-A2 ARYL FUSED AZAPOLYCYCLIC COMPOUNDS PFIZER PRODUCTS INC. (US) 2005-01-27 WO claimed
US-20050020616-A1 Aryl fused azapolycyclic compounds PFIZER INC 2005-01-27 US claimed
US-20050020616-A1 Aryl fused azapolycyclic compounds PFIZER INC 2005-01-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050020616-A1 Aryl fused azapolycyclic compounds GRIN2C, GRIN2A, GRIN2B GPR119 440/4885IRAK4 3156/4885KDM4E 783/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.